| Literature DB >> 33156940 |
Caroline Soi1, Jessica C Shearer2, Ashwin Budden3, Emily Carnahan2, Nicole Salisbury2, Gilbert Asiimwe4, Baltazar Chilundo5, Haribondhu Sarma6, Sarah Gimbel7, Moses Simuyemba8, Jasim Uddin6, Felix Masiye8, Moses Kamya9, Dai Hozumi10, Julie K Rajaratnam2, Stephen S Lim11.
Abstract
Vaccination, like most other public health services, relies on a complex package of intervention components, functioning systems and committed actors to achieve universal coverage. Despite significant investment in immunization programmes, national coverage trends have slowed and equity gaps have grown. This paper describes the design and implementation of the Gavi Full Country Evaluations, a multi-country, prospective, mixed-methods approach whose goal was to monitor and evaluate processes, inputs, outputs and outcomes of immunization programmes in Bangladesh, Mozambique, Uganda and Zambia. We implemented the Full Country Evaluations from 2013 to 2018 with the goal of identifying the drivers of immunization programme improvement to support programme implementation and increase equitable immunization coverage. The framework supported methodological and paradigmatic flexibility to respond to a broad range of evaluation and implementation research questions at global, national and cross-country levels, but was primarily underpinned by a focus on evaluating processes and identifying the root causes of implementation breakdowns. Process evaluation was driven by theories of change for each Gavi funding stream (e.g. Health Systems Strengthening) or activity, ranging from global policy development to district-level programme implementation. Mixing of methods increased in relevance and rigour over time as we learned to build multiple methods into increasingly tailored evaluation questions. Evaluation teams in country-based research institutes increasingly strengthened their level of embeddedness with immunization programmes as the emphasis shifted over time to focus more heavily on the use of findings for programme learning and adaptation. Based on our experiences implementing this approach, we recommend it for the evaluation of other complex interventions, health programmes or development assistance.Entities:
Keywords: Evaluation; health systems; immunization; implementation research
Year: 2020 PMID: 33156940 PMCID: PMC7646739 DOI: 10.1093/heapol/czaa127
Source DB: PubMed Journal: Health Policy Plan ISSN: 0268-1080 Impact factor: 3.344
Design elements of a prospective, mixed-methods, comprehensive, process-focused evaluation
| Element | The FCE approach |
|---|---|
| Overarching objectives |
Phase 1 (2013–16): to understand and quantify the barriers to and drivers of immunization programme improvement, including Gavi’s contributions Phase 2 (2017–18): to evaluate the new policies, programmes and processes implemented by the Gavi strategy for the 2016–2020 period with a focus on identifying the drivers of equitable coverage and Gavi’s contribution to observed changes |
| Time frame | Prospective |
| Knowledge paradigm and disciplines | Mixed paradigms (positivist and relativist) and multidisciplinary [implementation science, evaluation, epidemiology, biostatistics, public health, social science (policy science, organizational science, health services research), economics] |
| Methods | Multiple, mixed methods driven by the EQ or phenomenon of interest |
| Scope | All aspects of the results chain and all levels of intervention (from global policies and process to national and subnational implementation) related to Gavi investments and national immunization programmes |
| Data sources | Multiple data sources, often triangulated to answer a single question. An emphasis on fit-for-purpose data collection tailored to specific EQs |
| Analytic approach | Multiple analytic approaches based on fit with EQ and evidence needs. Methods and analytic approaches were increasingly purposively mixed over time as we improved question framing to allow mixing. |
| Generalizability and comparability | Use of ToCs and conceptual frameworks support comparability across multiple countries |
| Evaluators and participants | Evaluators were staff of national universities or research institutions, and global research institutions at global level. Evaluators shifted from independent arms-length evaluators to, in some cases, participant-observers of EPI processes and decisions. Global and national immunization stakeholders participated in the design of the evaluation and selection of EQs. |
| Dissemination and feedback loops | Over time, the consortium implemented regular dissemination and feedback to key national-level stakeholders (e.g. active participation during EPI meetings, quarterly policy briefs), including specific and targeted recommendations |
| Governance | Commissioned by the Evaluation Advisory Committee, a sub-committee of the Gavi Board composed of independent evaluation advisors. Funded by Gavi, and managed by the evaluation team at the Gavi Secretariat. |
Figure 1Evaluation approach
Sequential vs simultaneous mixing
| Sequential mixing of methods | Simultaneous mixing of methods |
|---|---|
| We frequently used quantitative data sources to identify low coverage or sub-optimal routinization of a new vaccine and used qualitative methods to identify the root causes. In Mozambique, e.g. we observed low coverage of measles second dose (MSD) through examination of routine HMIS data. The evaluation team in Mozambique developed hypotheses to explain low coverage and tested them through in-depth interviews with national and sub-national EPI stakeholders. | We used multiple methods simultaneously to answer the FCE EQ related to partnership (‘What is the effectiveness, efficiency, and country ownership of national immunization partnerships and their contribution program performance’.). We employed social network mapping and qualitative interviews at the same time to develop a holistic understanding of how the structure of immunization partnerships influenced their performance and observed outcomes ( |
Figure 2Example ToC (process of introducing pneumococcal conjugate vaccine)
Figure 3Revised conceptual framework of the drivers of vaccination coverage and equity
Summary of methods and data sources
| Method | Stage of results chain | Purpose | Data sources | Example finding |
|---|---|---|---|---|
| Process tracking | All, except impact. | Monitored fidelity of programme activities and outputs against ToC to identify successes and challenges during programme implementation |
Meeting observation of EPI technical working group and other key meetings, increasingly structured over time (e.g. using structured checklists) Document review of Gavi grant applications, budgets and performance frameworks (i.e. M&E frameworks), EPI policies, plans and strategies, published literature Vaccines doses administered from HMIS Fact checking interviews to clarify whether something occurred, to facilitate description of the process In-depth interviews to understand why and how the processes unfolded as observed | See the 2016 cross-country report for how years of process tracking was used to explain years of HSS grant implementation delays across FCE countries |
| RCA | All, except impact. |
Generates and tests hypotheses about the underlying causes of key programme success and challenges against all available evidence Synthesizes relevant evidence for developing key findings and recommendations | Desk review, key informant and fact-checking interviews, analysis of HMIS data | See |
| Small-area estimates of vaccine coverage | Outcomes | Improve granularity of estimates of vaccine coverage in FCE countries to inform recommendations for resource targeting | Household surveys | Small-area estimates identified sub-national inequalities in each country |
| Observational study of determinants and constraints of effective vaccine coverage (Phillips | Outputs to outcomes | Identify determinants of effective vaccine coverage to inform recommendations for improvement |
Household surveys with linked sero-surveys and health facility surveys Systematic review | See |
| Resource tracking | Inputs | Estimate national resource envelopes and sources |
Document review KIIs | Resource tracking results were reported in 2016 country reports and paved the way for further analyses of fiscal space and financing scenarios in 2017 |
| Partnership/network analysis | Any (but primarily inputs to activities) | Evaluate the effectiveness, efficiency and country ownership of national immunization partnerships and their contribution programme performance |
Social network surveys Document review In-depth interviews | We analysed the structure and composition of the Uganda HPV vaccine introduction partners’ network to explain successes and challenges observed during decision-making around HPV vaccine ( |
| Vaccine effectiveness study | Impact | Estimate the impact of pneumococcal conjugate vaccine (PCV) |
Nasopharyngeal carriage surveys Disease surveillance | Together, these studies provided strong evidence of the effectiveness and impact of PCV10 on nasopharyngeal carriage of vaccine-type pneumococcus and the incidence of vaccine-type invasive pneumococcal disease and pneumonia |
| Regression analyses | Impact | Estimate the impact of new vaccine introductions of PCV and rotavirus vaccines on child mortality |
Household surveys | Our analyses indicate that high coverage of new vaccines is associated with significant improvements in child mortality. In 2016, there were 10.1% (95% UI: 6.4, 13.8) and 11.9% (95% UI: 9.4, 14.3) reductions in under-5 mortality in Mozambique and Zambia, respectively, compared with scenarios where these vaccines were not introduced |
| District case studies (Phase 2) | Inputs to activities to outputs to outcomes | Identify the drivers of district performance |
HMIS data Document review In-depth interviews with district managers and health workers | District case studies identified barriers and enablers of vaccine coverage; see e.g. Uganda’s 2017–18 report ( |
Figure 4RCA diagram from Mozambique
Identifying the determinants of sub-optimal coverage of new vaccines in Mozambique
| In 2015 Mozambique set out to introduce rotavirus vaccine, inactivated poliovirus vaccine (IPV) and MSD. The FCE team in Mozambique observed the planning for introduction closely, as the joint introduction of three vaccines was hypothesized to be a significant stretch of a relatively small national immunization programme. Through observation, document review and interviews, we concluded that the launch of these vaccines and their related activities (health worker trainings, communications activities, updating data systems) went smoothly in large part due to lessons learned from previous vaccine introductions (pentavalent in 2009; PCV in 2013) and high political will and commitment. However, using HMIS data, the FCE team observed that the number of doses administered of these new vaccines was lower than of the existing routine vaccines ( Late arrival of first-quarter vaccine consignments. Customs clearance challenges which protracted the procurement process. Lack of regional warehouses in the central and northern regions. Insufficient air transport capacity to deliver stock to central and northern regions. Global supply shortages of IPV. Because the FCE team was also continually tracking the process of implementing the country’s Health Systems Strengthening grant, they understood that many of the observed issues were caused by delays in receiving and implementing HSS funding from Gavi, which in turn had their own global and local root causes. The team’s ability to demonstrate the consequences of the HSS delays on vaccine coverage and suggest actionable recommendations led to changes in technical assistance in Mozambique and informed Gavi’s global reforms to HSS funding in 2016. |
Strengths and weaknesses of the prospective evaluation approach and its influence on the implementation of Gavi support and EPI programmes
| Successful example | Unsuccessful example | Opportunity for stronger evaluation design |
|---|---|---|
| Example 1: Feedback loops worked when individual, institutional and contextual factors aligned | ||
| During year 1 of the evaluation in Mozambique, we found two major bottlenecks in the preparation for the introduction of PCV. First, the vaccine introduction grant funds were disbursed late by Gavi and only arrived in the country 2 weeks prior to the official launch of the vaccine resulting in lack of country readiness (e.g. the National Immunization Program did not have time to update immunization registers or prepare for adequate monitoring). Second, MoH and partners did not pilot social mobilization media messages resulting in the erroneous invitation of all infants rather than only the target age group (babies aged 4 months). Consequently, there was overuse of available doses and ensuing stock outs of PCV. On receiving these results both Gavi and Mozambique’s National Immunization Program made immediate process rectifications for the upcoming HPV vaccine introduction. Gavi disbursed funds 8 months prior to the launch and the National Immunization Program piloted HPV vaccine social media mobilization messages before widely implementing them. | Unfortunately, the findings from Mozambique’s PCV introduction in the first year of the FCE (e.g. that new vaccine introductions were sub-optimally planned) were repeated in almost every country for every new vaccine introduction, including in Mozambique for introductions in the years following the PCV introduction. The FCE evaluators continually recommended to Gavi that they play a more active role in determining introduction readiness, and specifically that countries and partner reflect on and propose adaptations based on previous new vaccine introduction experiences. The existence of these recommendations in reports, policy briefs, and in presentations were likely not married with adequate advocacy to Gavi or countries to ensure that they were sufficiently adopted. | Future prospective evaluations/IR platforms should invest more heavily in the use of evaluation findings for real-time and ongoing programme adjustments, which requires adequate resources for communications and advocacy, capacity building and institutionalization of a culture of learning and adaptation. |
|
| ||
| Example 2: Feedback loops were often too slow for larger policies or decisions | ||
| A major focus of the evaluation was Gavi’s HPV vaccine ‘demonstration project’ policy—a policy that required countries to first demonstrate that they could achieve adequate coverage of HPV vaccine in select regions prior to applying for funding for national introduction. Evaluators found that Gavi’s policy incentivized countries to invest heavily in achieving high coverage rates in non-representative regions with greater demand and access to services; because of the incentive to demonstrate high coverage, learnings from these projects were of little relevance for national introduction and more challenging contexts. FCE evaluators communicated these and other findings to Gavi and over a period of multiple years and Gavi eventually reformed their policies and approaches to supporting decision-making, introduction and implementation of HPV vaccine based on FCE findings and other evidence. | It took Gavi multiple years to finalize the changes to their HPV vaccine policies and procedures, and in the meantime little action was taken both by Gavi and among partners to transfer cross-country lessons and adapt within countries. This contributed to sub-optimal implementation in countries that did decide to introduce (e.g. Uganda, Bangladesh) and delayed introductions in Zambia and Mozambique due to perceptions that lessons from the demonstration projects were not generalizable. These bottlenecks could have been avoided with faster and more adaptive engagement of Gavi and other Alliance partners. | Future prospective evaluations should experiment with approaches to supporting the timely adaptive management of programmes. This may mean more direct engagement with key decision-makers, or an agreement that learnings from the evaluation will be discussed and responded to by decision-makers |
|
| ||
| Example 3: Evaluation teams were not adequately embedded in programme decision-making | ||
| Over time, evaluation teams strengthened their relationships and level of embeddedness with programme implementers. When evaluators were present during decision-making processes, they were able to add findings and evidence from the evaluation. This occurred in Bangladesh for their HSS-2 application (the evaluation team invited to participate on the technical working group), during Mozambique’s planning meetings for national HPV vaccine introduction, and frequently in Uganda where the team was the most embedded with the EPI programme. | In other cases, evaluators were not present for key decisions and that limited the incorporation of evidence from the FCE. In some cases—particularly in the early years of the evaluation—evaluators were present in decision-making meetings but felt unsure of whether and how to inform the decision without biasing it and calling into question their role as an independent evaluator. | Future prospective evaluations should encourage evaluators to be embedded in programmes. |